Genetic Testing in South Africa

By Crystal Lubbe

February 13, 2025

Could genetic testing be the key to preventing sudden cardiac deaths in South Africa? The recent study investigated the use of genetic testing in South Africa, specifically through next-generation sequencing (NGS), to identify genetic causes of sudden unexpected deaths (SUD) in a young South African cohort. It analysed DNA from 51 SUD cases, focusing on 49 genes linked to inherited cardiac arrhythmogenic disorders. The findings revealed that approximately 4% of the deaths were likely due to genetic arrhythmic or cardiac conduction disorders. This study highlights the importance of genetic testing in understanding and preventing sudden cardiac deaths in South Africa.

Key Insights into Genetic Testing

The study identified 175 different missense variants, with 92.5% being known and documented, and 7.4% being novel. Most variants were of benign or likely benign significance, while a small percentage were pathogenic or of unknown significance. Post-mortem genetic testing revealed that about 4% (2/51) of the SUD cases had a genetic arrhythmic or cardiac conduction disorder as the probable cause of death. The study emphasises the need for better detection, treatment, and prevention of sudden cardiac deaths in South Africa, especially in light of the significant increase in noncommunicable diseases, particularly cardiovascular diseases. Utilising NGS and the Galaxy bioinformatic platform for variant annotation and interpretation demonstrates the potential of advanced genetic testing to elucidate the causes of sudden unexpected deaths.

Public Health Concerns Globally

Sudden cardiac death is a major public health concern globally. In sub-Saharan Africa, including South Africa, it accounts for an estimated 50% of all cardiovascular deaths. Unfortunately, there is a lack of reliable statistics on its incidence in these regions.
Previous studies have shown the value of genetic testing in determining the underlying causes of sudden unexpected deaths, especially in cases where traditional post-mortem investigations are inconclusive. Research indicates that sudden deaths are more common among males, particularly in the 40-49 age group, and often result from cardiovascular and respiratory incidents. Genetic factors are identified in a small percentage of these cases.

The Transformative Role of Genetic Testing in South Africa: Implications for Health and Society

The integration of next-generation sequencing (NGS) into the investigation of sudden unexpected deaths in South Africa could have profound economic implications. By reducing the need for repeated and costly diagnostic procedures, early identification of genetic causes can lead to targeted preventive measures and treatment strategies, potentially lowering healthcare costs over time. From a public health perspective, the insights gained from genetic testing can significantly inform strategies aimed at preventing sudden cardiac deaths. By identifying genetic predispositions, public health programs can focus on genetic screening and counseling, ultimately leading to improved health outcomes and reduced mortality rates.

For families affected by sudden unexpected deaths, genetic testing offers the possibility of closure by providing a clearer understanding of the cause of death. It also has important genetic implications for family members, enabling early intervention and preventive measures that can safeguard their health. Moreover, the study emphasises the necessity for more comprehensive epidemiological data on sudden cardiac deaths in South Africa. Such data is crucial for policymakers to develop and implement effective health strategies and interventions, addressing the growing burden of cardiovascular diseases.

In conclusion, genetic testing in South Africa is an essential tool for uncovering the underlying genetic causes of sudden unexpected deaths. It not only enhances healthcare outcomes but also helps in devising strategies to mitigate associated risks, thereby playing a transformative role in the health and well-being of individuals and communities.

Reference url

Recent Posts

Trump drug price reform
     

A Systems Dynamics Approach to Lowering Drug Prices by 30–80% in the US

💡 Can the U.S. lower drug prices by 30–80% while improving access and preserving innovation?

President Trump’s recent Executive Order lays the groundwork for bold reforms—targeting international price gaps, PBM markups, and regulatory delays.

This article applies a systems dynamics approach to identify leverage points and feedback loops driving high U.S. drug costs—and outlines concrete, policy-based strategies to reverse them.

Explore how systemic thinking can drive sustainable, scalable change in U.S. pharmaceutical pricing.

#SyenzaNews #DrugPricing #HealthcarePolicy #SystemsThinking #PharmaInnovation

EU Multiannual Financial Framework
     

EFPIA Advocates for Stronger Life Sciences in EU Multiannual Financial Framework

💡 How can the EU strengthen its pharmaceutical sector for the future?

The EFPIA has laid out critical recommendations for the next EU Multiannual Financial Framework (2028-2034), focusing on boosting funding for life sciences research, enhancing regulatory competitiveness, and improving health data infrastructure. These insights could significantly shape the future landscape of healthcare in Europe.

Dive into the full article to learn how these recommendations aim to propel innovation and increase access to medicines across Europe!

#SyenzaNews #pharmaceuticals #healthcarepolicy

NICE health technology evaluations
        

Evolving NICE Health Technology Evaluations: Enhancing Patient Perspectives and Addressing Health Inequalities

🌟 Are you ready to embrace a new era in health technology evaluations?

Our latest article dives into the recent updates from NICE regarding the incorporation of patient perspectives and tackling health inequalities in their health technology assessments. By exploring stakeholder feedback and proposed methodologies, we uncover a shift towards more inclusive and transparent evaluations that could reshape market access and reimbursement policies in the UK healthcare system.

Don’t miss out on these vital insights that could impact your understanding of healthcare value! Read the full article [here](https://www.nice.org.uk/process/pmg36/documents/consultation-comments-and-responses).

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.